NFKB1 and neoplasm: Here, we investigated the HIV-1 reactivating potential of a treatment combining HDACIs used in human clinical trials or therapies (such as VPA and suberoylanilide hydroxamic acid [SAHA]) and an NF-κB inducer with no tumor-promoting effects, prostratin.